Orthostatic Hypotension and Antihypertensive Treatment in Lung Transplant Recipients: A Cross-Sectional Study
Zurich Open Repository and Archive (University of Zurich) · 09.01.2025
DOI: 10.5167/uzh-267727 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Zurich Open Repository and Archive (University of Zurich), erschienen am 09.01.2025. Verfasst von Bradicich und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
Lung transplant is the ultimate treatment of many end-stage lung diseases. Calcineurin inhibitors, crucial in immunosuppression for lung transplant recipients, are linked to secondary hypertension, necessitating antihypertensive treatment. In addition, lung transplant recipients frequently experience orthostatic hypotension, occasionally stemming from autonomic dysfunction, but also commonly attributed as a negative side effect of antihypertensive treatment. Our study aimed to evaluate the frequency of orthostatic blood pressure irregularities and investigate the involvement of antihypertensive treatment as a potential risk factor in the occurrence among lung transplant recipients. Materials and methods Fifty-six consecutive lung transplant recipients, both inpatient and outpatient, at the University Hospital Zurich (Switzerland) were monitored from 1999 to 2013. Transplant recipients underwent a Schellong test (an active standing test). Our evaluation encompassed their initial traits, such as the existence of supine hypertension. We computed the odds ratio for the comparison of the likelihood of experiencing orthostatic hypotension while using a minimum of 1 type of antihypertensive medication versus absence of antihypertensive drugs.
Results
Of the lung transplant recipients, 25% showed a positive Schellong test. Within this group, 64% had supine hypertension, and 29% displayed symptoms of orthostatic hypotension. Among the patients, 71% were using at least 1 type of antihypertensive medication. The odds ratio for showing orthostatic hypotension while taking at least 1 type of antihypertensive drug versus the absence of antihypertensive medications was 1.64 (95% exact CI, 0.39-6.90) with P = .50. This finding remained consistent regardless of age, sex, inpatient or outpatient status, and the duration since transplant.
Conclusions
Orthostatic blood pressure dysregulation is prevalent among lung transplant recipients, frequently without noticeable symptoms. In our cohort, the use of antihypertensive medications did not elevate the risk of orthostatic hypotension.
Schlagwörter
Zitieren
APA
Bradicich, Matteo, Schuurmans, M, M., Pazhenkottil, P, A., Steinack, Carolin, Hillinger, Sven, Hage, & René (2025). Orthostatic Hypotension and Antihypertensive Treatment in Lung Transplant Recipients: A Cross-Sectional Study. Zurich Open Repository and Archive (University of Zurich). https://doi.org/10.5167/uzh-267727
Vancouver
Bradicich, Matteo, Schuurmans, M M, Pazhenkottil, P A, et al. Orthostatic Hypotension and Antihypertensive Treatment in Lung Transplant Recipients: A Cross-Sectional Study. Zurich Open Repository and Archive (University of Zurich). 2025. doi:10.5167/uzh-267727
BibTeX
@article{Bradicich2025,
author = {Bradicich and Matteo and Schuurmans and M, Macé and Pazhenkottil and P, Aju and Steinack and Carolin and Hillinger and Sven and Hage and René},
title = {Orthostatic Hypotension and Antihypertensive Treatment in Lung Transplant Recipients: A Cross-Sectional Study},
journal = {Zurich Open Repository and Archive (University of Zurich)},
year = {2025},
doi = {10.5167/uzh-267727}
}
EUVIMED